The FDA has approved a drug from New Haven-based BioXcel Therapeutics for the treatment of agitation associated with schizophrenia or bipolar disorder in adults.
The FDA ruled that BioXcel’s IGALMI, a single-dose film formulation of dexmedetomidine, was safe and effective for use in acute cases of agitation. The drug is the company’s first FDA-approved product.